Generic Medicine Info
Indications and Dosage
Adult: As sulfate: 12.5 mg bid. Max: 50 mg bid.
Renal Impairment
Dosage adjustments may be needed.
Hepatic Impairment
Dosage adjustments may be needed.
Severe tachycardia, dissecting aortic aneurysm, heart failure with high cardiac output, cor pulmonale, MI due to mechanical obstruction, idiopathic SLE and related disorders. Porphyria. 1st 2 trimesters during pregnancy.
Special Precautions
Ischaemic heart disaease, MI, cerebrovascular disorders, renal or hepatic impairment. Monitor for postural hypotension and tachycardia during initial therapy if given to patients with heart failure. Gradual withdrawal is advisable.
Adverse Reactions
Tachycardia, palpitations, angina pectoris, severe headache, GI disturbances, flushing, dizziness, nasal congestion, postural hypotension, fluid retention with oedema and wt gain, conjunctivitis, lachrymation, tremor, peripheral neuropathy with numbness and tingling of extremities, muscle cramps, hepatotoxicity, blood dyscrasias, haemolytic anaemia, difficulty in urinating, glomerulonephritis, constipation, paralytic ileus, depression, anxiety, hypersensitivity reactions, eosinophilia. A condition resembling SLE with prolonged use of large doses.
Drug Interactions
Agents with hypotensive action, diazoxide, thiazide diuretics.
Mechanism of Action: Dihydralazine is a direct-acting vasodilator which acts predominantly on the arterioles. It reduces BP and peripheral resistance thus increasing cardiac output. It also tends to improve renal and cerebral blood flow and its effect on diastolic pressure is more marked than on systolic pressure.
MIMS Class
Other Antihypertensives
Disclaimer: This information is independently developed by MIMS based on Dihydralazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in